Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Replimune Group, Inc. (REPL : NSDQ)

• Company Description    Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company's product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. Number of Employees: 479

• Price / Volume Information    Yesterday's Closing Price: $10.77 Daily Weekly Monthly 20 Day Moving Average: 1,179,790 shares Shares Outstanding: 77.09 (millions) Market Capitalization: $830.22 (millions) Beta: 0.61 52 Week High: $17.00 52 Week Low: $6.44 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 8.95% 4.87% 12 Week 34.71% 13.31% Year To Date -11.06% -16.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 Unicorn Park Drive Suite 303 - WOBURN,MA 01801 USA ph: 781-222-9600 fax: - ir@replimune.com http://www.replimune.com

• General Corporate Information    Officers Sushil Patel - Chief Executive Officer and Director Emily Hill - Chief Financial Officer Andrew Schwendenman - Chief Accounting Officer Philip Astley-Sparke - Director Kapil Dhingra - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 76029N106 SIC: 2836 Fiscal Year Fiscal Year End: March Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 77.09 Most Recent Split Date: (:1) Beta: 0.61 Market Capitalization: $830.22 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.79 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.04 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.99 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -3.80% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -57.98 12/31/24 - -54.84 ROA 06/30/25 - - 03/31/25 - -45.21 12/31/24 - -42.97 Current Ratio 06/30/25 - - 03/31/25 - 7.95 12/31/24 - 11.43 Quick Ratio 06/30/25 - - 03/31/25 - 7.95 12/31/24 - 11.43 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 5.40 12/31/24 - 7.05 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.17 12/31/24 - 0.14 Debt-to-Capital 06/30/25 - - 03/31/25 - 14.25 12/31/24 - 12.49

Powered by Zacks Investment Research ©